| Literature DB >> 27029387 |
Bo Chen1, Qi-Cong Luo2, Jian-Bo Chen3, Li-E Lin4, Ming-Xu Luo5, Hong-Yue Ren6, Pei-Qiong Chen7, Lian-Guo Shi7.
Abstract
Cell plasma membrane proteins, playing a crucial role in cell malignant transformation and development, were the main targets of tumor detection and therapy. In this study, CyDye/biotin double-labeling proteomic approach was adopted to profile the membrane proteome of gastric cancer cell line BGC-823 and paired immortalized gastric epithelial cell GES-1. Real-time PCR, Western blotting, and immunohistochemical staining were used to validate the differential expression of a novel identified cell surface marker R-cadherin in gastric cancer cells and tissues. Clinicopathological study and survival analysis were performed to estimate its roles in tumor progression and outcome prediction. Real-time PCR and Western blotting showed that the expression level of R-cadherin in gastric cancer were significantly lower than non-cancerous epithelial cell and tissues. Clinicopathological study indicated that R-cadherin was dominantly expressed on cell surface of normal gastric epithelium, and its expression deletion in gastric cancer tissues was associated with tumor site, differentiation, lymph node metastasis, and pTNM (chi-square test, P < 0.05). Those patients with R-cadherin positive expression displayed better overall survivals than negative expression group (log-rank test, P = 0.000). Cox multivariate survival analysis revealed lacking the expression of R-cadherin was a main independent predictor for poor clinical outcome in gastric cancer (RR = 5.680, 95 % CI 2.250-14.341, P < 0.01). We have established a fundamental membrane proteome database for gastric cancer and identified R-cadherin as a tumor differentiation and progression-related cell surface marker of gastric cancer. Lacking the expression of R-cadherin indicates poor prognosis in patients with gastric cancer.Entities:
Keywords: Cell surface proteins; Gastric adenocarcinoma; R-cadherin; Tumor biomarker; Tumor differentiation; Tumor progression
Mesh:
Substances:
Year: 2016 PMID: 27029387 PMCID: PMC5080335 DOI: 10.1007/s13277-016-5032-z
Source DB: PubMed Journal: Tumour Biol ISSN: 1010-4283
Fig 1Fluorescence labeling and separation of cell surface proteins in BGC-823 and GES-1 cells. a, b In situ labeling of cell surface proteins with CyDyes DIGE fluors in BGC-823 (a) and GES-1 cells (b). c–e Extracts of fluors-labeled cell surface proteins from BGC-823 (lines 1–3) and GES-1 (lines 4–6) were separated by SDS-PAGE electrophoresis and imaged by typhoon imager scanner using 488-nm laser (c) and silverstaining (d), and the protein bands cut off for LC-MS analysis were indicated in e, green line
Fig 2Characteristics of 36 membrane proteins. a Molecular weight; b PI range; c Functional classification; d LC-MS of R-cadherin in cell surface of BGC-823 GC cell
Characteristics of 36 cell plasma membrane proteins
| ID | Protein name | MW | PI | TMDs | GRAVY |
|---|---|---|---|---|---|
| Binding and structural proteins | |||||
| IPI00796440 | Peroxisomal membrane protein 2 (PXMP2) | 41447.36 | 10.64 | 4 | 0.165 |
| IPI00382470 | Heat shock protein HSP 90-alpha (HSP 86) | 98161.31 | 5.07 | 0 | −0.754 |
| IPI00022426 | Protein AMBP | 38999.49 | 5.95 | 0 | −0.341 |
| IPI00290035 | Protocadherin-15 | 216069.72 | 4.94 | 1 | −0.266 |
| IPI00024034 | Cadherin 4 (R-cadherin) | 100280.55 | 4.65 | 1 | −0.301 |
| IPI00218795 |
| 43617.75 | 6.96 | 1 | −0.411 |
| IPI00022759 | Geranylgeranyl transferase type-1 subunit beta | 42396.38 | 6.37 | 0 | −0.272 |
| IPI00290770 | T-complex protein 1 subunit alpha | 60462.75 | 6.1 | 1 | −0.171 |
| IPI00554711 | Junction plakoglobin | 81744.71 | 5.75 | 0 | −0.157 |
| Cell proliferation, differentiation and apoptosis related proteins | |||||
| IPI00045337 | Tumor necrosis factor receptor superfamily member 13C (TNFRSF13C) | 18863.8 | 8.47 | 2 | −0.127 |
| IPI00000690 | Apoptosis-inducing factor 1, mitochondrial (AIFM1) | 66900.63 | 9.04 | 2 | −0.227 |
| IPI00013933 | Desmoplakin | 331774.4 | 6.44 | 0 | −0.823 |
| IPI00025753 | Desmoglein-1 | 113715.49 | 4.9 | 1 | −0.285 |
| IPI00179330 | Ubiquitin-40S ribosomal protein S27a (RPS27A) | 17964.86 | 9.68 | 0 | −0.489 |
| IPI00017726 | 3-Hydroxyacyl-CoA dehydrogenase type-2 | 26923.03 | 7.65 | 0 | 0.227 |
| IPI00220644 | Pyruvate kinase isozymes M1/M2 | 41447.36 | 10.64 | 0 | −0.132 |
| Signaling proteins and receptor | |||||
| IPI00555605 | Peripheral plasma membrane protein CASK | 104520.22 | 6.02 | 0 | −0.426 |
| IPI00402234 | Ras-associated and pleckstrin homology domains-containing protein 1 (RAPH1) | 72873.77 | 5.91 | 0 | −0.65 |
| IPI00027462 | Protein S100-A9 (S100A9) | 13241.95 | 5.71 | 0 | −0.895 |
| IPI00017292 | Catenin beta-1 (CTNNB1) | 85496.55 | 5.53 | 0 | −0.175 |
| IPI00010470 | Synaptosomal-associated protein 25 (SNAP25) | 23315.08 | 4.66 | 0 | −0.865 |
| IPI00465156 | Adenylate cyclase type 4 (ADCY4) | 119794.61 | 7.31 | 12 | 0.152 |
| Ion channel and transport protein | |||||
| IPI00020542 | Solute carrier family 22 member 11 (SLC22A11) | 59971.64 | 8.96 | 10 | 0.463 |
| IPI00007188 | ADP/ATP translocase 2 (SLC25A5) | 32895.2 | 9.76 | 3 | 0.045 |
| IPI00031422 | Sodium channel protein type 5 subunit alpha (SCN5A) | 224941.21 | 5.38 | 21 | 0.008 |
| IPI00440493 | ATP synthase subunit alpha, mitochondrial (ATP5A1) | 59750.67 | 9.16 | 0 | −0.106 |
| IPI00303476 | ATP synthase subunit beta, mitochondrial (ATP5B) | 56559.96 | 5.26 | 0 | −0.020 |
| Cell cycle-associated proteins | |||||
| IPI00784201 | Centrosomal protein of 290 kDa (CEP290) | 290544.28 | 5.75 | 0 | −0.955 |
| IPI00007765 | Stress-70 protein, mitochondrial (HSPA9) | 73680.41 | 5.87 | 0 | −0.402 |
| IPI00014238 | Lysyl-tRNA synthetase (KARS) | 68048.11 | 5.94 | 0 | −0.454 |
| Metabolism-associated proteins | |||||
| IPI00219018 | Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) | 36053.05 | 8.57 | 0 | −0.114 |
| IPI00029009 | Phosphatidylinositol-4-phosphate 5-kinase type-1 gamma (PIP5K1C) | 73260.32 | 5.17 | 0 | −0.488 |
| IPI00550128 | Long-chain-fatty-acid--CoA ligase (ACSBG1) | 81258.26 | 5.73 | 0 | −0.263 |
| Other annotated proteins | |||||
| IPI00785084 | Ig gamma-1 chain C region (IGHG1) | 52286.28 | 8.84 | 0 | −0.365 |
| IPI00376931 | Synaptotagmin-15 (SYT15) | 52224.69 | 8.83 | 1 | −0.258 |
| IPI00292836 | Uncharacterized protein C9orf174 (C9orf174) | 191100.07 | 5.74 | 1 | −0.648 |
Fig 3Expression of CDH4/R-cadherin in gastric cancer tissues and cell lines. a, b qRT-PCR analysis of CDH4 mRNA expression in N vs. T of 17 GC patients. c, d Western blot analysis of R-cadherin expression in N vs. T of 8 GC patients. T: GC tissues; N: the adjacent non-cancerous mucosa. *P < 0.05, student t test. e Western blot analysis of R-cadherin expression in immortalized gastric epithelial cell GES-1 and three GC cell lines with different degrees of differentiation and invasive
Fig 4R-cadherin expression in GC and non-cancerous tissues. a Mucosa of chronic gastritis; b Well-differentiated upper GC; c Middle-differentiated upper GC; d Poor-differentiated distal GC (pT2N0M0); e Poor-differentiated middle GC (pT2N3aM0); f Vascular cancer embolus in pool-differentiated GC (pT1bN1M0)
Correlationship between R-cadherin expression and clinicopathological variables
| Clinicopathological variables | R-cadherin ICH staining | Chi-square test | |
|---|---|---|---|
| Negative | Positive |
| |
| Gender | |||
| Male | 98 | 19 | 0.889 |
| Female | 44 | 8 | |
| Age | |||
| ≤60 | 76 | 11 | 0.223 |
| >60 | 66 | 16 | |
| Tumor site | |||
| Upper | 16 | 8 | 0.012 |
| Middle and distal | 126 | 19 | |
| Tumor size | |||
| ≤5 cm | 75 | 18 | 0.185 |
| >5 cm | 67 | 9 | |
| Differentiation | |||
| Well and moderate | 26 | 11 | 0.010 |
| Poor and undifferentiation | 116 | 16 | |
| Invasion depth | |||
| T1-T2 | 31 | 10 | 0.091 |
| T3-T4 | 111 | 17 | |
| Lymph node metastasis | |||
| Negative | 29 | 12 | 0.008 |
| Positive | 113 | 15 | |
| pTNM stage | |||
| I–II | 44 | 14 | 0.036 |
| III–IV | 98 | 13 | |
Fig 5Kaplan-Meier curves and log-rank test for the overall survival of GC patients according to age (a), tumor size (b), invasion depths (c), lymph node metastasis (d), pTNM stage (e), and ICH staining of R-cadherin (f)
The overall survival related to several clinicopathological variables with gastric cancer patients
| Clinicopathological variables | Patient events | Median survival months | Log-rank test | |
|---|---|---|---|---|
| (95 % CI, %) |
| |||
| Gender | ||||
| Male | 84 | 65 | 21 (15.8–26.2) | 0.936 |
| Female | 39 | 30 | 22 (15.9–28.1) | |
| Age | ||||
| ≤60 | 66 | 49 | 27 (20.8–33.2) | 0.042 |
| >60 | 57 | 46 | 15 (10.1–19.9) | |
| Tumor size | ||||
| ≤5 cm | 68 | 50 | 28 (22.6–33.4) | 0.038 |
| >5 cm | 55 | 45 | 16 (11.5–20.5) | |
| Differentiation | ||||
| Well and moderate | 29 | 20 | 23 (17.7–28.3) | 0.345 |
| Poor and undifferentiation | 94 | 75 | 21 (16.7–25.3) | |
| Invasion depth | ||||
| T1-T2 | 29 | 12 | NA | 0.000 |
| T3-T4 | 94 | 83 | 19 (14.7–23.3) | |
| Lymph node metastasis | ||||
| Negative | 26 | 11 | NA | 0.000 |
| Positive | 97 | 84 | 19 (15.3–22.7) | |
| pTNM stage | ||||
| I–II | 38 | 23 | 46 (29.4–62.6) | 0.000 |
| III–IV | 85 | 72 | 18 (14.4–21.6) | |
| R-cadherin ICH staining | ||||
| Negative | 109 | 90 | 19 (15.6–22.4) | 0.000 |
| Positive | 14 | 5 | NA | |
NA, because the overall survival rates of these patients were more than 50 %, the median survival time cannot be calculated
Cox proportional hazard regression model analysis of all the patients
| Clinicopathological variables | Multivariate analysis | ||
|---|---|---|---|
| Age | Relative risk | 95 % CI |
|
| ≤60 vs. >60 | 0.570 | 0.376–0.864 | 0.008 |
| Tumor size | |||
| ≤5 cm vs. >5 cm | 0.911 | 0.591–1.405 | 0.673 |
| Invasion depth | |||
| T1-T2 vs. T3-T4 | 0.340 | 0.176–0.655 | 0.001 |
| Lymph node metastasis | |||
| Negative vs. positive | 0.495 | 0.244–1.002 | 0.051 |
| pTNM stage | |||
| I–II vs. III–IV | 0.865 | 0.500–1.496 | 0.604 |
| R-cadherin expression | |||
| Negative vs. positive | 5.680 | 2.250–14.341 | 0.000 |